Sobi Acquires Novimmune’s Emapalumab with its All Related Assets to Strengthen its Focus in Hematology and Immunology

Shots:

• Novimmune to receive $115.86M, out of $518.76M and has already received $402.9M under its exclusive license agreement signed with Sobi in 2018. Sobi to get IP & patent rights, associated employees of emapalumab with an option for shared financial rights to NI-1701 & NI-1801.
• Sobi has also received the US FDA’s PR voucher for emapalumab with an expected completion of the acquisition in Q3’19 and plans to establish a center of excellence in Sweden and Switzerland for hematology & immunology respectively
• Emapalumab is a mAb, binding to & neutralizing interferon gamma (IFNγ), indicated for HLH in pediatric & adults. In Jul’18, Novimmune grants exclusive global rights of emapalumab to Sobi which is now replaced with the acquisition

 Click here, Click here to read full press release/ article | Ref: Sobi | Image:Laboratory focus